Cargando…
Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer
INTRODUCTION: Inhibitor of apoptosis (IAPs) proteins are a family of proteins that can block apoptosis in normal cells and have been suggested to cause resistance to apoptosis in cancer. Overexpression of oncogenic receptor tyrosine kinases is common in breast cancer; in particular 20% of all cases...
Autores principales: | Foster, Fiona M, Owens, Thomas W, Tanianis-Hughes, Jolanta, Clarke, Robert B, Brennan, Keith, Bundred, Nigel J, Streuli, Charles H |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716510/ https://www.ncbi.nlm.nih.gov/pubmed/19563669 http://dx.doi.org/10.1186/bcr2328 |
Ejemplares similares
-
Analysis of inhibitor of apoptosis protein family expression during mammary gland development
por: Owens, Thomas W, et al.
Publicado: (2010) -
Combined Inhibition of ErbB1/2 and Notch Receptors Effectively Targets Breast Ductal Carcinoma In Situ (DCIS) Stem/Progenitor Cell Activity Regardless of ErbB2 Status
por: Farnie, Gillian, et al.
Publicado: (2013) -
Inhibitor of apoptosis proteins as a therapeutic target in breast cancer
por: Foster, FM, et al.
Publicado: (2008) -
Bax Exists in a Dynamic Equilibrium between the Cytosol and Mitochondria to Control Apoptotic Priming
por: Schellenberg, Barbara, et al.
Publicado: (2013) -
BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
por: Miele, Evelina, et al.
Publicado: (2020)